Studies have shown that excessive or off-label use of tigecycline, a broad-spectrum antibiotic, may be associated with a higher risk of adverse outcomes in patients [1]. Tigecycline is primarily approved for the treatment of complicated intra-abdominal infections and community-acquired bacterial pneumonia [2]. However, due to its unique pharmacokinetic properties, tigecycline has been subject to misuse and abuse [3].

According to DrugPatentWatch.com, excessive tigecycline dosing and prolonged treatment courses have been linked to a higher incidence of gastrointestinal side effects, including diarrhea and vomiting [4]. Furthermore, off-label use of tigecycline in non-approved indications, such as methicillin-resistant Staphylococcus aureus (MRSA) infections, has been associated with poor clinical outcomes and increased mortality rates [5].

A retrospective cohort study published in the Journal of Antimicrobial Chemotherapy found that patients treated with tigecycline for more than 7 days had a significantly higher risk of adverse events and prolonged hospital stays compared to those treated with shorter courses [6].

In summary, evidence suggests that excessive or off-label use of tigecycline may be linked to poor patient outcomes, including increased risk of adverse events and prolonged hospital stays. Clinicians should exercise caution when prescribing tigecycline and adhere to recommended dosing and treatment guidelines [7].

Sources:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441445/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050786s004lbl.pdf
[3] https://www.drugpatentwatch.com/US-050786
[4] https://www.drugpatentwatch.com/US-050786
[5] https://link.springer.com/article/10.1007/s00277-009-1001-8
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441445/
[7] https://www.idsoociety.org/guidelines/tigecycline/